
Amgen Inc.
AMGNHealthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38
Financials
Financial Snapshot
Market Cap
$248.92B
Enterprise Value
$289.73B
Revenue (TTM)
$38.93B
Net Income (TTM)
$9.39B
Cash & Investments
$13.19B
Net Cash
-$40.82B
Free Cash Flow (TTM)
$9.58B
Operating CF (TTM)
$12.04B
Debt/Equity
3.76
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $38.09B | $41.68B | $29.30B | $8.91B | $10.65B | $8.04B | $9.30B | $10.94B | $11.97B | $9.13B | $13.19B | |
| Operating Cash Flow | $10.35B | $11.18B | $11.30B | $9.15B | $10.50B | $9.26B | $9.72B | $8.47B | $11.49B | $9.96B | $12.04B | |
| Free Cash Flow | $9.52B | $10.51B | $10.56B | $8.53B | $9.89B | $8.38B | $8.79B | $7.36B | $10.39B | $8.10B | $9.58B | |
| Capital Expenditure | -$837.0M | -$664.0M | -$738.0M | -$618.0M | -$608.0M | -$880.0M | -$936.0M | -$1.11B | -$1.10B | -$1.86B | -$2.45B | |
| Financing Cash Flow | -$2.60B | -$6.59B | -$22.49B | -$15.77B | -$4.87B | -$8.27B | -$4.04B | $21.05B | -$9.41B | -$10.86B | -$5.66B |
R&D Spending
R&D (TTM)
$7.85B
R&D Intensity
20.2%
R&D Growth vs Prior
+12.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.99B | $22.85B | $23.75B | $23.36B | $25.42B | $25.98B | $26.32B | $28.19B | $33.42B | $36.74B | $38.93B | |
| R&D Expense | $3.84B | $3.56B | $3.74B | $4.12B | $4.21B | $6.32B | $4.43B | $4.78B | $5.96B | $6.97B | $7.85B | |
| R&D % of Revenue | 16.7% | 15.6% | 15.7% | 17.6% | 16.5% | 24.3% | 16.8% | 17.0% | 17.8% | 19.0% | 20.2% | |
| SG&A | $5.06B | $4.87B | $5.33B | $5.15B | $5.73B | $5.37B | $5.41B | $6.18B | $7.10B | $7.05B | $6.96B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.99B | $22.85B | $23.75B | $23.36B | $25.42B | $25.98B | $26.32B | $28.19B | $33.42B | $36.74B | $38.93B | |
| Cost of Revenue | $4.16B | $4.07B | $4.10B | $4.36B | $6.16B | $6.45B | $6.41B | $8.41B | $12.86B | $10.73B | $10.13B | |
| Gross Profit | $18.83B | $18.78B | $19.65B | $19.01B | $19.27B | $19.52B | $19.92B | $19.77B | $20.57B | $26.01B | $28.80B | |
| R&D | $3.84B | $3.56B | $3.74B | $4.12B | $4.21B | $6.32B | $4.43B | $4.78B | $5.96B | $6.97B | $7.85B | |
| SG&A | $5.06B | $4.87B | $5.33B | $5.15B | $5.73B | $5.37B | $5.41B | $6.18B | $7.10B | $7.05B | $6.96B | |
| Operating Income | $9.79B | $9.97B | $10.26B | $9.67B | $9.14B | $7.64B | $9.57B | $7.90B | $7.26B | $10.68B | $13.83B | |
| Interest Expense | $1.26B | $1.30B | $1.39B | $1.29B | $1.26B | $1.20B | $1.41B | $2.88B | $3.15B | $2.75B | $2.64B | |
| Pretax Income | $9.16B | $9.60B | $9.54B | $9.14B | $8.13B | $6.70B | $7.35B | $7.86B | $4.61B | $8.98B | $11.05B | |
| Net Income | $7.72B | $1.98B | $8.39B | $7.84B | $7.26B | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B | $9.39B | |
| EPS (Diluted) | 10.24 | 2.69 | 12.62 | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 17.24 | |
| EBITDA | $12.53B | $12.86B | $12.88B | $12.63B | $13.00B | $11.30B | $12.17B | $14.80B | $13.36B | $16.90B | $18.17B | |
| Shares Out. (M) | 754.00 | 735.00 | 665.00 | 609.00 | 590.00 | 573.00 | 541.00 | 538.00 | 541.00 | 542.00 | 546.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.24B | $3.80B | $6.95B | $6.04B | $6.27B | $7.99B | $7.63B | $10.94B | $11.97B | $9.13B | $13.19B | |
| Short-Term Investments | $34.84B | $37.88B | $22.36B | $2.87B | $4.38B | $48.0M | $1.68B | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $46.01B | $49.48B | $37.62B | $18.44B | $21.14B | $19.39B | $22.19B | $30.33B | $29.03B | $29.06B | $34.36B | |
| Total Assets | $77.63B | $79.95B | $66.42B | $59.71B | $62.95B | $61.16B | $65.12B | $97.15B | $91.84B | $90.59B | $96.05B | |
| Total Current Liabilities | $11.20B | $9.02B | $13.49B | $12.84B | $11.65B | $12.18B | $15.69B | $18.39B | $23.10B | $25.49B | $23.23B | |
| Long-Term Debt | $30.19B | $34.19B | $29.51B | $26.95B | $32.90B | $33.22B | $37.35B | $63.17B | $56.55B | $50.01B | $51.61B | |
| Total Liabilities | $47.75B | $54.71B | $53.92B | $50.03B | $53.54B | $54.47B | $61.46B | $90.92B | $85.96B | $81.93B | $81.70B | |
| Stockholders' Equity | $29.88B | $25.24B | $12.50B | $9.67B | $9.41B | $6.70B | $3.66B | $6.23B | $5.88B | $8.66B | $14.35B | |
| Retained Earnings | -$438.0M | -$5.07B | -$17.98B | -$21.33B | -$21.41B | -$24.60B | -$28.62B | -$26.55B | -$27.59B | -$25.11B | -$19.81B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $10.35B | $11.18B | $11.30B | $9.15B | $10.50B | $9.26B | $9.72B | $8.47B | $11.49B | $9.96B | $12.04B | |
| Capital Expenditure | -$837.0M | -$664.0M | -$738.0M | -$618.0M | -$608.0M | -$880.0M | -$936.0M | -$1.11B | -$1.10B | -$1.86B | -$2.45B | |
| Free Cash Flow | $9.52B | $10.51B | $10.56B | $8.53B | $9.89B | $8.38B | $8.79B | $7.36B | $10.39B | $8.10B | $9.58B | |
| Investing Cash Flow | -$8.66B | -$4.02B | $14.34B | $5.71B | -$5.40B | $733.0M | -$6.04B | -$26.20B | -$1.05B | -$1.94B | -$2.63B | |
| Financing Cash Flow | -$2.60B | -$6.59B | -$22.49B | -$15.77B | -$4.87B | -$8.27B | -$4.04B | $21.05B | -$9.41B | -$10.86B | -$5.66B | |
| Issuance of Stock | $55.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | -$2.96B | -$3.16B | -$17.79B | -$7.70B | -$3.49B | -$4.97B | -$6.36B | $0.00 | -$200.0M | $0.00 | $0.00 | |
| Net Debt Issuance | $3.59B | $71.0M | -$1.12B | -$4.51B | $2.46B | $795.0M | $6.62B | $25.68B | -$4.26B | -$5.68B | -$152.0M | |
| Stock Based Comp. | $311.0M | $329.0M | $311.0M | $308.0M | $330.0M | $341.0M | $401.0M | $431.0M | $530.0M | $494.0M | $493.0M | |
| Net Change in Cash | -$903.0M | $559.0M | $3.15B | -$908.0M | $229.0M | $1.72B | -$360.0M | $3.31B | $1.03B | -$2.84B | $3.75B |
Dilution Tracker
Shares Outstanding
541M
5-Year Share Growth
-8.1%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 754.00 | 735.00 | 665.00 | 609.00 | 590.00 | 573.00 | 541.00 | 538.00 | 541.00 | 542.00 | 546.00 | |
| Change vs Prior % | — | -2.5% | -9.5% | -8.4% | -3.1% | -2.9% | -5.6% | -0.6% | 0.6% | 0.2% | 0.7% | |
| Stock Issuance | $55.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | -$2.96B | -$3.16B | -$17.79B | -$7.70B | -$3.49B | -$4.97B | -$6.36B | $0.00 | -$200.0M | $0.00 | $0.00 | |
| Stock Based Comp. | $311.0M | $329.0M | $311.0M | $308.0M | $330.0M | $341.0M | $401.0M | $431.0M | $530.0M | $494.0M | $493.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 81.9% | 82.2% | 82.7% | 81.4% | 75.8% | 75.2% | 75.7% | 70.1% | 61.5% | 70.8% | 74.0% | |
| Operating Margin % | 42.6% | 43.6% | 43.2% | 41.4% | 35.9% | 29.4% | 36.3% | 28.0% | 21.7% | 29.1% | 35.5% | |
| Net Margin % | 33.6% | 8.7% | 35.3% | 33.6% | 28.6% | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% | 24.1% | |
| EBITDA Margin % | 54.5% | 56.3% | 54.3% | 54.1% | 51.1% | 43.5% | 46.2% | 52.5% | 40.0% | 46.0% | 46.7% | |
| FCF Margin % | 41.4% | 46.0% | 44.5% | 36.5% | 38.9% | 32.3% | 33.4% | 26.1% | 31.1% | 22.0% | 24.6% | |
| ROE % | 25.8% | 7.8% | 67.2% | 81.1% | 77.2% | 88.0% | 179.0% | 107.8% | 69.6% | 89.1% | 85.6% | |
| ROA % | 9.9% | 2.5% | 12.6% | 13.1% | 11.5% | 9.6% | 10.1% | 6.9% | 4.5% | 8.5% | 9.8% | |
| ROIC % | 11.7% | 2.9% | 15.7% | 16.7% | 15.9% | 13.7% | 16.7% | 8.4% | 8.9% | 13.2% | 15.6% | |
| R&D / Revenue % | 16.7% | 15.6% | 15.7% | 17.6% | 16.5% | 24.3% | 16.8% | 17.0% | 17.8% | 19.0% | 20.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.1% | -0.6% | 3.9% | -1.6% | 8.8% | 2.2% | 1.3% | 7.1% | 18.6% | 9.9% | |
| Gross Profit | 8.0% | -0.3% | 4.6% | -3.3% | 1.4% | 1.3% | 2.0% | -0.7% | 4.0% | 26.5% | |
| Operating Income | 15.6% | 1.8% | 2.9% | -5.7% | -5.5% | -16.4% | 25.2% | -17.4% | -8.1% | 47.1% | |
| Net Income | 11.3% | -74.4% | 324.2% | -6.6% | -7.4% | -18.9% | 11.2% | 2.5% | -39.1% | 88.5% | |
| EPS (Diluted) | 13.0% | -73.7% | 369.1% | 2.1% | -4.4% | -16.5% | 17.8% | 3.1% | -39.5% | 88.2% | |
| Operating Cash Flow | 14.1% | 7.9% | 1.1% | -19.0% | 14.7% | -11.8% | 5.0% | -12.9% | 35.6% | -13.3% | |
| Free Cash Flow | 12.9% | 10.5% | 0.4% | -19.2% | 15.9% | -15.2% | 4.8% | -16.2% | 41.2% | -22.1% | |
| R&D Expense | -5.7% | -7.2% | 4.9% | 10.1% | 2.2% | 50.3% | -29.9% | 7.9% | 24.7% | 16.9% | |
| SG&A Expense | 4.5% | -3.8% | 9.5% | -3.4% | 11.3% | -6.3% | 0.9% | 14.1% | 14.8% | -0.6% | |
| Total Assets | 8.5% | 3.0% | -16.9% | -10.1% | 5.4% | -2.8% | 6.5% | 49.2% | -5.5% | -1.4% | |
| Book Value / Share | 7.3% | -13.5% | -45.2% | -15.5% | 0.4% | -26.8% | -42.1% | 71.2% | -6.7% | 48.1% | |
| Debt | 10.1% | 2.2% | -4.0% | -11.9% | 10.3% | 1.0% | 16.9% | 65.9% | -7.0% | -9.1% | |
| Diluted Shares | -1.6% | -2.5% | -9.5% | -8.4% | -3.1% | -2.9% | -5.6% | -0.6% | 0.6% | 0.2% |
Valuation
P/E (TTM)26.49
10Y Low / Med / High14.17 / 21.76 / 64.17
P/S6.39
10Y Low / Med / High4.22 / 5.37 / 6.24
P/B17.36
10Y Low / Med / High3.66 / 19.14 / 38.60
EV/EBITDA15.95
10Y Low / Med / High11.23 / 13.43 / 14.18
EV/Revenue7.44
10Y Low / Med / High5.66 / 6.55 / 7.37
P/FCF25.98
10Y Low / Med / High11.49 / 15.30 / 21.74
Intrinsic Value Models (per share)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 14.17 | 64.17 | 15.33 | 18.60 | 18.54 | 21.76 | 21.56 | 22.93 | 34.20 | 22.84 | 26.49 | |
| P/S Ratio | 4.76 | 5.56 | 5.42 | 6.24 | 5.30 | 4.94 | 5.37 | 5.47 | 4.22 | 4.79 | 6.39 | |
| P/B Ratio | 3.66 | 5.04 | 10.29 | 15.08 | 14.32 | 19.14 | 38.60 | 24.73 | 23.99 | 20.34 | 17.36 | |
| EV/EBITDA | 11.23 | 12.34 | 12.08 | 13.43 | 12.42 | 13.59 | 14.18 | 14.04 | 14.16 | 13.11 | 15.95 | |
| EV/Revenue | 6.12 | 6.94 | 6.55 | 7.26 | 6.35 | 5.91 | 6.56 | 7.37 | 5.66 | 6.03 | 7.44 |
Analyst Estimates & Quality
Altman Z-Score
2.55
Grey Zone
Piotroski F-Score
8
Strong
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $39.42B | $41.23B | $43.02B |
| Net Income | $12.69B | $13.38B | $14.12B |
| EPS | $23.49 | $24.97 | $26.73 |
| # Analysts (EPS) | 16 | 20 | 11 |
Dividends
Dividend/Share (TTM)
$9.94
Dividend Yield
2.16%
Frequency
Quarterly
Next Payment
Dec 11, 2026
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Nov 20, 2026 | Dec 11, 2026 | $2.52 | Quarterly |
| Aug 21, 2026 | Sep 11, 2026 | $2.52 | Quarterly |
| May 15, 2026 | Jun 5, 2026 | $2.52 | Quarterly |
| Feb 13, 2026 | Mar 6, 2026 | $2.52 | Quarterly |
| Nov 21, 2025 | Dec 12, 2025 | $2.38 | Quarterly |
| Aug 22, 2025 | Sep 12, 2025 | $2.38 | Quarterly |
| May 16, 2025 | Jun 6, 2025 | $2.38 | Quarterly |
| Feb 14, 2025 | Mar 7, 2025 | $2.38 | Quarterly |
| Nov 18, 2024 | Dec 9, 2024 | $2.25 | Quarterly |
| Aug 16, 2024 | Sep 6, 2024 | $2.25 | Quarterly |
| May 16, 2024 | Jun 7, 2024 | $2.25 | Quarterly |
| Feb 15, 2024 | Mar 7, 2024 | $2.25 | Quarterly |
| Nov 16, 2023 | Dec 8, 2023 | $2.13 | Quarterly |
| Aug 17, 2023 | Sep 8, 2023 | $2.13 | Quarterly |
| May 17, 2023 | Jun 8, 2023 | $2.13 | Quarterly |
| Feb 14, 2023 | Mar 8, 2023 | $2.13 | Quarterly |
| Nov 16, 2022 | Dec 8, 2022 | $1.94 | Quarterly |
| Aug 17, 2022 | Sep 8, 2022 | $1.94 | Quarterly |
| May 16, 2022 | Jun 8, 2022 | $1.94 | Quarterly |
| Feb 14, 2022 | Mar 8, 2022 | $1.94 | Quarterly |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Product and Service, Other | $1.18B | $1.68B | $1.52B | $1.28B | $1.40B | $1.60B |
| Aranesp | $1.57B | $1.48B | $1.42B | $1.36B | $1.34B | $1.39B |
| ENBREL | $5.00B | $4.46B | $4.12B | $3.70B | $3.32B | $2.23B |
| Kyprolis | $1.06B | $1.11B | $1.25B | $1.40B | $1.50B | — |
| Neulasta | $2.29B | $1.73B | $1.13B | — | — | — |
| Otezla | $2.19B | $2.25B | $2.29B | $2.19B | $2.13B | $2.27B |
| Other Products | $6.57B | $5.85B | $5.57B | $5.26B | $5.63B | $7.26B |
| Prolia | $2.76B | $3.25B | $3.63B | $4.05B | $4.37B | $4.41B |
| Repatha (evolocumab) | $887.0M | $1.12B | $1.30B | $1.64B | $2.22B | — |
| XGEVA | $1.90B | $2.02B | $2.01B | $2.11B | $2.23B | $2.08B |
| Nplate | — | $1.03B | $1.31B | $1.48B | $1.46B | $1.52B |
| Evenity | — | — | $787.0M | $1.16B | — | — |
| BLINCYTO | — | — | — | $861.0M | $1.22B | $1.56B |
| KRYSTEXXA | — | — | — | $272.0M | $1.19B | $1.34B |
| TEPEZZA | — | — | — | $448.0M | $1.85B | $1.90B |
| Vectibix | — | — | — | $984.0M | $1.04B | $1.18B |
| EVENITY | — | — | — | — | $1.56B | $2.10B |
| TEZSPIRE | — | — | — | — | $972.0M | $1.48B |
| Repatha | — | — | — | — | — | $3.02B |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Non-US | $6.93B | $7.79B | $7.73B | $8.38B | $9.56B | $10.33B |
| UNITED STATES | $18.50B | $18.19B | $18.59B | $19.81B | $23.86B | $26.42B |